

**AMSTER  
ROTHSTEIN  
& EBENSTEIN LLP**

*Intellectual Property Law*

90 Park Avenue  
New York NY 10016

Main 212 336 8000

Fax 212 336 8001

Web [www.arelaw.com](http://www.arelaw.com)



*Partners*

Morton Amster  
Jesse Rothstein (1934 - 2003)  
Daniel Ebenstein  
Philip H. Gottfried  
Michael J. Berger  
Neil M. Zipkin  
Anthony F. Lo Cicero  
Kenneth P. George  
Abraham Kasdan, Ph.D.  
Ira E. Silfin  
Chester Rothstein  
Craig J. Arnold  
Kenneth M. Bernstein

*Senior Counsel*

Charles R. Macedo  
Mark J. Rosenberg  
Nancy M. Dodderidge

*Of Counsel*

Jerry D. Dainow

*Associates*

Neal L. Rosenberg  
Patrick Boland\*  
Trebzor Lloyd  
Joseph M. Casino  
John S. Economou

*Michael V. Solomita*

Holly Pekowsky  
Michael P. Kenney  
Marion P. Metelski  
Max Vern  
Dana R. Metes  
Karl J. Kolbinger  
Brian A. Comack  
Richard S. Mandaro  
Marc J. Jason  
Elie H. Gendloff, Ph.D.  
David Mitnick  
Charles W. Rath  
David A. Boag

*Karen J. Bernstein*

Matthieu Hausig  
Jung S. Hahm  
Reiko Kaji  
Alan D. Miller, Ph.D.  
Hsin-Hsin (Ginger) Liu  
John A. Lepore\*  
Norajean McCaffrey

*\*Not admitted in New York*

06/23/04

IFW

June 22, 2004

Elie H. Gendloff, Ph.D., Esq.

Direct 212 336 8108

E-mail [egendlof@arelaw.com](mailto:egendlof@arelaw.com)

Via Express Mail

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

"Express Mail" mailing label No. EL 996377643 US	
Date of Deposit:	June 22, 2004
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Name:	Elie H. Gendloff
Signature:	

Re: U.S. Utility Patent Application Serial No. 10/624,080

Filed July 21, 2003

Title: INHIBITION OF HIV-1 VIRION PRODUCTION BY  
A TRANSDOMINANT MUTANT OF INTEGRASE  
INTERACTOR 1(INI1)/hSNF5

Inventor: Ganjam V. Kalpana

Our File: 96700/819

Dear Sir:

Enclosed please find the following documents for filing with the above-identified utility patent application in the name of Ganjam V. Kalpana, entitled INHIBITION OF HIV-1 VIRION PRODUCTION BY A TRANSDOMINANT MUTANT OF INTEGRASE INTERACTOR 1(INI1)/hSNF5, comprising the following:

1. Submission of Information Disclosure Statement (2 pages);
2. Information Disclosure Statement by Applicant, Forms PTO/SB/08A and PTO/SB/08B (2 pages total) with twenty (20) references cited therein and attached thereto (19 paper-copy references and 1 reference on CD-ROM); and
3. Return receipt postcard.

Commissioner for Patents  
Serial No. 10/624,080

-2-


June 22, 2004

Please acknowledge receipt of the enclosed papers by stamping the enclosed postcard and returning same to us.

Respectfully submitted,

Amster, Rothstein & Ebenstein LLP  
Attorneys for Applicants  
90 Park Avenue  
New York, NY 10016  
212 336 8000


Dated: New York, New York  
June 22, 2004

By:   
Elie H. Gendloff  
Registration No. 44,704



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/624,080  
Applicants : Ganjam V. Kalpana  
Filed : July 21, 2003  
Art Unit : 1645  
Examiner : Not Yet Assigned  
Docket No. : 96700/819  
Customer No. : 1912

"Express Mail" mailing label No.	EL 996377643 US
Date of Deposit:	June 22, 2004
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Name:	Elie H. Gendloff
Signature:	

SUBMISSION INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§§ 1.56, 1.97, and 1.98, applicants enclose herewith Forms PTO/SB/08A and PTO/SB/08B, containing twenty (20) references which may be deemed relevant to the above-identified application, along with a paper copy of nineteen (19) of the references and a CR-ROM containing one reference (CHIN, A., University of North Carolina), cited therein. The enclosed items are made of record to assist the U.S. Patent and Trademark Office in its examination of the above-identified application. The Examiner is respectfully requested fully to consider the enclosed items, and independently to assess their teachings.


Submission of IDS  
Appl. No. 10/624,080  
Filed July 21, 2003  
Amdt. dated June 22, 2004


No fee is deemed necessary for the filing of this Information Disclosure Statement. However, if any unanticipated fee is required to maintain pendency of this application, authorization is hereby given to charge any such fee to Deposit Account No. 01-1785.

Respectfully submitted

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicant  
90 Park Avenue  
New York, NY 10016  
(212) 336-8000

Dated: New York, New York  
June 22, 2004

By:   
Elie H. Gendloff  
Registration No.: 44,704



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/624,080		
		Filing Date	July 21, 2003		
		First Named Inventor	Ganjam V. Kalpana		
		Art Unit	1645		
		Examiner Name	to be assigned		
Sheet	1	of	2	Attorney Docket Number	96700/819

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	Biegel, J.A. et al., "Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors"; Cancer Res., Vol. 59, pp 74-9 (1999).	
	2	BUKOVSKY, A. et al., "Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease"; J. Virol., Vol. 70, No. 10, pp 6820-25 (1996).	
	3	CHENG, S.W. et al., "c MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function"; Nat. Genet., Vol. 22, No. 1, pp 102-05 (1999).	
	4	ENGLEMAN, A. et al., "Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication"; J. Virol., Vol. 69, No. 5, pp 2729-36 (1995).	
	5	FLETCHER, T.M. et al. "Complementation of integrase function in HIV-1 virions"; EMBO. J., Vol. 16, No. 16, pp 5123-38 (1997).	
	6	KALPANA, G.V. et al., "Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5"; Science, Vol. 266, pp 2002-6 (1994).	
	7	KINGSTON, R.E. et al., "ATP-dependent remodeling and acetylation as regulators of chromatin fluidity"; Genes & Dev., Vol. 13, pp 2339-52 (1999).	
	8	LEAVITT, A.D., et al., "Human Immunodeficiency Virus Type 1 Integrase Mutants Retain In Vitro Integrase Activity yet Fail to Integrate Viral DNA Efficiently during Infection"; J. Virol., Vol. 70, No. 2, pp 721-28 (1996).	
	9	LEE, D. et al., "Interaction of E1 and hSNF5 proteins stimulates replication of human papillomavirus DNA"; Nature, Vol. 399, pp 487-91 (1999).	
	10	LEE, D. et al., "SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53 mediated transcription"; J. Biol. Chem., Vol. 277, No. 25, pp 22330-37 (2002).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/624,080		
		Filing Date	July 21, 2003		
		First Named Inventor	Ganjam V. Kalpana		
		Art Unit	1645		
		Examiner Name	to be assigned		
Sheet	2	of	2	Attorney Docket Number	96700/819

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	11	MOROZOV, A., et al., "Structure-function analysis of integrase interactor 1/hSNF5L1 reveals differential properties of two repeat motifs present in the highly conserved region"; Proc. Natl. Acad. Sci. USA, Vol. 95, pp 1120-25 (1998).	
	12	NAKAMURA, T. et al., "Lack of infectivity of HIV-1 integrase zinc finger-like domain mutant with morphologically normal maturation"; Biochem. Biophys. Res. Commun., Vol. 239, pp 715-22 (1997).	
	13	ROZENBLATT-ROSEN, O., et al., "The C terminal SET domains of ALL 1 and TRITHORAX interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex"; Proc. Natl. Acad. Sci. USA, Vol. 95, pp 4152-57 (1998).	
	14	VERSTEEGE, I. et al., "Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer"; Nature, Vol. 394, pp 203-06 (1998).	
	15	WANG, W. et al., "Purification and biochemical heterogeneity of the mammalian SWI-SNF complex"; EMBO. J., Vol. 15, pp 5370-82 (1996).	
	16	WISKERCHEN et al., "Human immunodeficiency virus type 1 integrase: Effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells"; J. Virol., Vol. 69, No. 1, pp 376-86 (1995).	
	17	WU, D.Y. et al., "Epstein Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/INI1"; J. Virol., Vol. 70, No. 9, pp 6020-28 (1996).	
	18	WU, X. et al., "Human immunodeficiency Virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex"; J. Virol., Vol. 73, No. 3, pp 2126-35 (1999).	
	19	YUNG, E. et al., "Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1"; Nature Med., Vol. 7, No. 8, pp 920-26 (2001).	
	20	CHIN, A., "On the preparation and utilization of isolated and purified oligonucleotides." Kathrine R. Everett Law Library of the University of North Carolina, March 14, 2002. (on attached CD-ROM)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.